Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

MLA

Chen, Robert, et al. “Five-Year Survival and Durability Results of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma.” Blood, vol. 128, no. 12, Sept. 2016, pp. 1562–66. EBSCOhost, https://doi.org/10.1182/blood-2016-02-699850.

APA

Chen, R., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Connors, J. M., Engert, A., Larsen, E. K., Huebner, D., Fong, A., & Younes, A. (2016). Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood, 128(12), 1562–1566. https://doi.org/10.1182/blood-2016-02-699850

Chicago

Chen, Robert, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Joseph M. Connors, et al. 2016. “Five-Year Survival and Durability Results of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma.” Blood 128 (12): 1562–66. doi:10.1182/blood-2016-02-699850.